Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 8887 results

  1. Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke

    In development Reference number: GID-IPG10439 Expected publication date:  11 February 2027

  2. Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]

    In development Reference number: GID-TA11959 Expected publication date: TBC

  3. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

  4. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    Awaiting development Reference number: GID-TA11497 Expected publication date: TBC

  5. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    In development Reference number: GID-TA11782 Expected publication date: TBC

  6. Norucholic acid for treating primary sclerosing cholangitis [ID6583]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 8 April 2026.

  7. Ex-situ machine perfusion devices for lung transplants

    In development Reference number: GID-HTE10084 Expected publication date:  21 October 2026

  8. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    In development Reference number: GID-NG10434 Expected publication date:  02 December 2026

  9. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

  10. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date: TBC

  11. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

  12. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  13 May 2026

  13. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

  14. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]

    Awaiting development Reference number: GID-TA11861 Expected publication date: TBC

  15. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  18 June 2026